NCT00443261View on ClinicalTrials.gov

Azacitidine and Cisplatin for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

PHASE1TerminatedINTERVENTIONAL

Enrollment

1

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2008

Study Completion Date

June 30, 2008

Conditions

Squamous Cell Carcinoma

Interventions

DRUG

Azacitidine

SC azacitidine

DRUG

Cisplatin

cisplatin 75 mg/m\^2 day 8 every 28 days

Trial Locations (1)

64128

Kansas City VA Medical Center, Kansas City

Sponsors

Collaborators (1)

Celgene Corporation

All Listed Sponsors

collaborator

Celgene Corporation

INDUSTRY

lead

University of Kansas Medical Center

OTHER